BARCELONA—Researchers have documented a small but significant stage migration in metastatic bladder cancer between 1988 and 2006.

The FDA has approved Cysview (hexaminolevulinate HCl), an optical imaging agent indicated for use in the cystoscopic detection of non-muscle-invasive papillary bladder cancer in patients suspected or known to have lesions on the basis of prior cystoscopy.

Even 30 or more years after their last exposure to aromatic amines, which are known bladder carcinogens, individuals have an excess risk of bladder cancer, a study found.

CHICAGO—A novel drug called eribulin may be effective for advanced urothelial cancer (UC), even in patients with prior adjuvant or neoadjuvant chemotherapy, according to new data presented at the American Society of Clinical Oncology annual meeting.

A 12-year study of 1,762 individuals found that the risk of bladder cancer is about 1.5 times higher among people who eat the most red meat compared with those who eat the least, especially when the food is cooked at high temperatures or eaten well done.

In a recent study, zoledronic acid decreased the incidence of skeletal-related events (SREs) and improved one-year survival in patients with bone metastases from bladder cancer, according to a study.

VIENNA—Radical cystectomy should be considered in all cases of muscle-invasive, non-metastatic bladder cancer, according to Marek Babjuk, MD, PhD, who presented an evidence-based argument for this approach at the 7th Meeting of the European Association of Urology Section of Oncological Urology.

The trend followed changes in CMS policy that boosted reimbursement.

Intravesical instillations of epirubicin after transurethral resection (TUR) for non-muscle-invasive bladder tumors may be effective as prophylaxis against recurrence, according to investigators.

Gemcitabine might be a second-line treatment option for patients with high-risk non-muscle-invasive bladder cancer (BC) who fail therapy with bacille Calmette-Guérin (BCG), according to Italian researchers.